A test-and-not-treat strategy for onchocerciasis in loa loa-endemic areas

2017

Article référencé dans le Web of Science WOS:000415998800007

Kamgno J., Pion Sébastien, Chesnais Cédric, Bakalar M. H., D'Ambrosio M. V., Mackenzie C. D., Nana-Djeunga H. C., Gounoue-Kamkumo R., Njitchouang G. R., Nwane P., Tchatchueng-Mbouga J. B., Wanji S., Stolk W. A., Fletcher D. A., Klion A. D., Nutman T. B., Boussinesq Michel

New England Journal of Medicine, 2017, 377 (21), p. 2044-2052 ISSN 0028-4793

BACKGROUND Implementation of an ivermectin-based community treatment strategy for the elimination of onchocerciasis or lymphatic filariasis has been delayed in Central Africa because of the occurrence of serious adverse events, including death, in persons with high levels of circulating Loa loa microfilariae. The LoaScope, a field-friendly diagnostic tool to quantify L. loa microfilariae in peripheral blood, enables rapid, point-of-care identification of persons at risk for serious adverse events. METHODS A test-and-not-treat strategy was used in the approach to ivermectin treatment in the Okola health district in Cameroon, where the distribution of ivermectin was halted in 1999 after the occurrence of fatal events related to L. loa infection. The LoaScope was used to identify persons with an L. loa microfilarial density greater than 20,000 microfilariae per milliliter of blood, who were considered to be at risk for serious adverse events, and exclude them from ivermectin distribution. Active surveillance for posttreatment adverse events was performed daily for 6 days. RESULTS From August through October 2015, a total of 16,259 of 22,842 persons 5 years of age or older (71.2% of the target population) were tested for L. loa microfilaremia. Among the participants who underwent testing, a total of 15,522 (95.5%) received ivermectin, 340 (2.1%) were excluded from ivermectin distribution because of an L. loa microfilarial density above the risk threshold, and 397 (2.4%) were excluded because of pregnancy or illness. No serious adverse events were observed. Nonserious adverse events were recorded in 934 participants, most of whom (67.5%) had no detectable L. loa microfilariae. CONCLUSIONS The LoaScope-based test-and-not-treat strategy enabled the reimplementation of community-wide ivermectin distribution in a heretofore "off limits" health district in Cameroon and is a potentially practical approach to larger-scale ivermectin treatment for lymphatic filariasis and onchocerciasis in areas where L. loa infection is endemic.

Entomologie médicale / Parasitologie / Virologie [052]

CAMEROUN

Fonds IRD [F B010071379]

fdi:010071379